United States - English - NLM (National Library of Medicine)

chiesi usa, inc. - poractant alfa (unii: ke3u2023np) (poractant alfa - unii:ke3u2023np) - poractant alfa 80 mg in 1 ml - curosurf® (poractant alfa) intratracheal suspension is indicated for the rescue treatment of respiratory distress syndrome (rds) in premature infants.  curosurf reduces mortality and pneumothoraces associated with rds.  none. the safety and effectiveness of curosurf for the rescue treatment, including the reduction of mortality and pneumothoraces, of respiratory distress syndrome (rds) have been established in premature infants and the information on this use is discussed throughout the labeling. the safety and effectiveness of curosurf in the treatment of full term infants or older pediatric patients with respiratory failure has not been established.

United States - English - NLM (National Library of Medicine)

abbvie inc. - beractant (unii: s866o45pig) (beractant phospholipids - unii:lja7v5fcw8) - calfactant 25 mg in 1 ml - survanta is indicated for prevention and treatment (“rescue”) of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. none

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - poractant alfa, quantity: 80 mg/ml - suspension - excipient ingredients: sodium chloride; water for injections; sodium bicarbonate - for the treatment (rescue) of respiratory distress syndrome (rds) in premature infants and for prophylactic use in infants at risk of rds.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - poractant alfa, quantity: 80 mg/ml - suspension - excipient ingredients: sodium chloride; water for injections; sodium bicarbonate - for the treatment (rescue) of respiratory distress syndrome (rds) in premature infants and prophylactic use in infants at risk of rds.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - beractant, quantity: 25 mg/ml - suspension - excipient ingredients: colfosceril palmitate; tripalmitin; palmitic acid; sodium chloride; phosphatidyl choline; water for injections - prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants.

Canada - English - Health Canada

total health centre - polygonum punctatum - liquid - 1x - polygonum punctatum 1x - homeopathic products

Canada - English - Health Canada

dolisos canada inc. - polygonum punctatum - globules - 1x - polygonum punctatum 1x - homeopathic products

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

chiesi pharmaceuticals gmbh - poractant alfa - suspension endotracheal - 80mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - beractant - suspension for endotracheopulmonary instillation - 25mg/1ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

deeplaid pharmaco ltd. (homoeo) - polygonum punctatum - liquid